Research Area: Checkpoint & combination therapy
Development Stage: Optimization
Goal: Identify differences and mechanism in combined cell therapies
to follow our data >[/ce_button]
Polyfunctionality and Polyfunctional Strength are considerably increased in samples treated with ACT+NKTR-214 vs ACT+IL-2 (left). Sorted antigen-specific CD8+ T cells Thy1.+ from tumors and spleen D7 after ACT+NKTR-214 or ACT+IL-2 (3 mice/group) were stimulated and stained with anti-mouse CD8.
NKTR2-14 elicited more polyfunctional cell subsets in the adoptively transferred TCR-T cells in spleen and tumor compared to IL-2.1
to learn more >[/ce_button]
Immuno-PET imaging using cys-diabody (cDb) targeting CD8 in vivo shows significant T cells expansion in spleen for ACT+NKTR-214-treated mice. Representative CD8 cys-diabody immuno-PET/CT images acquired on D5 after treatment with ACT+IL-2 or ACT+NKTR-214 (n=3/group). I.V. injection of Zr-89 labeled anti-CD8 cDb was performed 24h prior imaging of C57/BL6 mice.
NKTR-214 increases expression of genes associated with T cell cytotoxicity and memory. Clustering of chemokines and their receptors, showing a general trend of increased expression in the ACT+NKTR-214 group.1